A Medical Device Daily

Quick Study Radiology (QSR; St. Louis), a company bringing to smaller community hospitals the radiology services typically available to large hospitals, reported that it has closed a $3.3 million Series D financing round led by Advantage Capital Partners. Fletcher Spaght Ventures, Eagle River and Mantic Investments also participated in the funding round.

The company said the funds will be used for working capital needs as it continues to increase its share of the radiology information systems market.

The company provides hospitals, imaging centers and physician groups in several states an integrated solution for storing, viewing and tracking digital radiology images.

In other financing activity:

Del Global Technologies (Franklin Park, Illinois) reported that the registration statement for its previously disclosed common stock rights offering was declared effective on Tuesday by the SEC.

The company will distribute non-transferable subscription rights to purchase up to an aggregate of 11,660,524 shares of the company’s common stock, par value 10 cents per share to persons who own shares of the common stock as of the close of business on Feb. 5, the record date for the rights offering.

Each holder of record will receive one subscription right for each share of the common stock owned that will entitle the holder to purchase one share of common stock for $1.05 a share. The company’s stockholders who exercise their basic subscription privilege in full will also be entitled to purchase additional shares pursuant to an over-subscription privilege.

Del Global Technologies makes high performance diagnostic imaging systems for medical, dental and veterinary applications through the Del Medical Systems Group.

Sontra Medical (Franklin, Massachusetts) reported that it closed a $660,000 common stock and warrant financing with Sherbrooke Partners, other accredited investors and members of Sontra’s board of directors and management.

Sontra said that the financing was originally expected to be for $600,000; however, as a result of increased investor interest, it was increased by $60,000.

The company issued 6.6 million shares of common stock for 10 cents a share and two-year warrants to purchase 1.65 million shares of common stock at 21 cents a share in the financing.

Certain members of Sontra’s board and management team invested $120,000 in the financing, as required by the investors as a closing condition to the transaction.

Sontra has been developing a noninvasive, continuous transdermal glucose monitor for principal use in the intensive care market. In addition, the company owns a platform technology, the SonoPrep permeation system, and other technology for transdermal delivery of large-molecule drugs and vaccines.

Bausch & Lomb (B&L; Rochester, New York) said it filed a Form 8-K with the SEC providing information concerning its outstanding bank and public debt, and also providing updated information concerning its financial expectations for 2006 and 2007.

On Jan. 26, the company said it amended the letter waivers in connection with its $400 million five-year revolving credit agreement, dated July 26, 2005, and the five-year $375 million term loan agreement, dated Nov. 29, 2005, in favor of Bausch & Lomb B.V. and guaranteed by the company. The amended letter waivers take effect on Jan. 31, and extend the termination date to April 30.

The waivers would terminate if, prior to April 30, there were to be a final determination to delist the company’s securities from the New York Stock Exchange.

B&L currently has a trading extension from the NYSE through March 1, subject to the company’s anticipated filing of its delayed annual report on Form 10-K for 2005, which filing the company said is “imminent.”